Since the Gas6/TAM axis has been already related with the development of liver and pulmonary fibrosis in other pathologies [75,172,173], and increased levels of circulating Gas6 have been detected at hospital admission in severe COVID-19 patients [27], an involvement of TAM signaling in COVID-19-related fibrosis can be hypothesized. The gene discussed is GAS6; the disease is COVID-19.